Glaxosmithkline Share News (GSK)

GlaxoSmithKline Sees Positive Results From Relvar Ellipta Study

UK drugs watchdog warns it will struggle if Britain leaves EU

By Ben Hirschler LONDON, May 23 (Reuters) - A British vote to leave the European Union would disrupt and could well delay the approval of new drugs, leaving UK regulators struggling to cope, the chairman of the country's medicines watchdog said on Monday. Michael Rawlins, who chairs t

UPDATE 1-Drugmakers eye volume growth as China cuts prices by up to 67 pct

(Adds comment from GSK China head and analyst) SHANGHAI/LONDON, May 20 (Reuters) - Chinese health authorities announced price cuts of up to two-thirds for three drugs on Friday in the latest move to reduce the cost of healthcare for patients in the world's second-biggest economy. The

China slashes GSK, AstraZeneca drug prices in cost-cutting drive

SHANGHAI/LONDON, May 20 (Reuters) - Chinese health authorities announced price cuts of up to two-thirds for three expensive drugs on Friday in the latest move to reduce the cost of healthcare for patients in the world's second-biggest economy. The National Health and Family Planning Commiss

Glaxo Presents Positive Breo Ellipta, Anoro Ellipta Data

UPDATE 2-Novartis splits drugs business into two, pharma chief to leave

* Epstein leaving to "explore new challenges from the U.S." * AstraZeneca's Hudson hired to head pharma business * Existing cancer leader Strigini to head oncology (Adds analyst comment, more on Novartis drug business) By John Miller and Ben Hirschler ZURICH/LONDON, May

Novartis splits drugs business into two, pharma chief to leave

ZURICH, May 17 (Reuters) - Novartis is splitting its pharmaceuticals division into two business units, one focused on cancer medicines and the second on other drugs, it said on Tuesday. It also said David Epstein, division head and chief executive of Novartis Pharmaceuticals, will leave the

UPDATE 2-AstraZeneca asthma drug hits goal, to enter competitive market

* Benralizumab likely to reach the market next year * Faces competition from newly approved GSK and Teva drugs * AstraZeneca facing a wave of patent expiries (Adds analyst comment, detail on Japan option) By Ben Hirschler LONDON, May 17 (Reuters) - AstraZeneca's drive to

AstraZeneca boosted by good results for biotech asthma drug

LONDON, May 17 (Reuters) - AstraZeneca's drive to rebuild its portfolio of new medicines received a boost on Tuesday with positive results for a biotech drug for severe asthma that the company has previously flagged as a potential $2 billion-a-year product. The antibody treatment benralizum

Sunday newspaper round-up: RBS, Shell, Cobham, BT, banks

(ShareCast News) - Royal Bank of Scotland is examining a range of radical options to help speed the long-delayed separation and flotation of its Williams & Glyn subsidiary, including a potential divestment of its NatWest brand. Banking sources have indicated to the Sunday Telegraph that RBS and its

Glaxo's Bexsero Meets Primary, Secondary Endpoints In Phase IIIb Study

LONDON MARKET MIDDAY: Mondi Stands Out As FTSE 100 Rises

BROKER RATINGS SUMMARY: Jefferies And Shore Say Hold AstraZeneca

UK cost body finally approves limited use of GSK's lupus drug

LONDON, May 10 (Reuters) - Britain's healthcare cost watchdog has finally approved GlaxoSmithKline's lupus drug Benlysta for limited use, after rejecting it since 2011 on the grounds that it failed to offer good value for money. The National Institute for Health and Care Excellence (NICE) s

UPDATE 2-South Africa seeks price cut for Roche's Herceptin cancer drug

(Adds updates with Roche comment) CAPE TOWN, May 10 (Reuters) - South Africa is in talks with Swiss pharmaceutical firm Roche to reduce the price of its breast cancer drug Herceptin, which currently costs 500,000 rand ($33,000) a year to treat one person and is unaffordable to most women, t